Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010

Executive Summary

• Onco-Innovations Limited announced the initiation of hepatocyte and liver microsome metabolism studies for ONC010, its lead nanoparticle-formulated PNKP inhibitor targeting solid tumors.
• The preclinical studies, contracted to Nucro-Technics, will evaluate metabolic stability across human, rat, and dog systems to characterize intrinsic clearance and degradation pathways.
• Generated data will directly support future toxicology studies, pharmacokinetic modeling, dose selection, and regulatory submissions as the company advances ONC010 toward a First-in-Human clinical trial.

Key Details

• Drug Candidate: ONC010, a nanoparticle-formulated PNKP inhibitor with an exclusive worldwide license to patented solid tumor-targeting technology.
• Study Scope: Hepatocyte and liver microsome metabolism studies designed to capture complementary metabolic data (broader cell-based activity vs. enzyme-focused metabolism).
• Contractor: Nucro-Technics, a Canadian provider of IND-enabling preclinical development services.
• Test Systems: Human, rat, and dog models to assess species-specific metabolism and metabolic degradation pathways.
• Primary Objectives: Characterize intrinsic clearance, map metabolic degradation pathways, and establish a complete understanding of ONC010 processing across relevant biological systems.
• Strategic Application: Data will inform future toxicology study design, pharmacokinetic modeling, clinical dose selection, and regulatory submissions.
• Development Context: Part of an integrated IND-enabling strategy, running parallel to ongoing ADME, bioanalytical, manufacturing, formulation, and clinical translation activities.
• Milestone Significance: Marks a critical step in the IND-enabling phase, directly paving the way for the company's First-in-Human study.

Notable Quotes

• Dr. Islam Mohamed, Chief Medical Officer: "Hepatocyte and microsome studies are foundational components of modern oncology drug development. The data generated are intended help characterize the metabolic profile of ONC010 and to potentially contribute to dose selection, safety assessment and overall development planning."
• Thomas O'Shaughnessy, Chief Executive Officer: "The initiation of IND-enabling preclinical studies marks an important milestone as the Company advances ONC010 toward our First in Human Study. Understanding how the molecule behaves across relevant species is critical for designing future toxicology studies and informing clinical translation strategies."